Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients
Status:
Terminated
Trial end date:
2011-02-23
Target enrollment:
Participant gender:
Summary
Cardiovascular disease and mortality is the largest comorbidity within the dialysis
population. Nearly 50% of hemodialysis patients will have congestive heart failure at
initiation. According to the most recent United States Renal Data System (USRDS), 40% of
incident dialysis patients will have a cardiovascular event or die within the first 9 months
of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial
cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3
fatty acid doses on cardiovascular parameters in an incident hemodialysis population.
Initially, this will be a pilot study. Ultimately, the information will be used to adequately
plan for a larger intervention trial using Omega-3 fatty acids in incident hemodialysis
patients.